# TB-500 Research: Mechanism, Thymosin Beta-4 Studies, and Human Data

> TB-500 research readout: the actin-sequestration mechanism of action, the thymosin beta-4 study record across wound, cardiac and CNS models, and the human-trial gap.

Mechanism first, then the model-by-model evidence, then the human-data line — each finding tagged for fragment versus full-length thymosin beta-4.

## TB-500 Mechanism of Action: Actin Sequestration and Angiogenesis

TB-500 carries thymosin beta-4's actin-binding LKKTETQ motif, and the mechanism starts there. X-ray crystallography of a gelsolin-domain-1–thymosin beta-4 hybrid bound to actin, resolved at 2 Angstrom, established that thymosin beta-4 forms a 1:1 complex with G-actin and sequesters the monomer by capping both ends, preventing polymerization [1]. This is the structural basis for the protein's role as the body's principal G-actin-buffering molecule: it holds a reserve of unpolymerized actin and so governs cytoskeletal dynamics, cell motility and migration.

From that single mechanism the downstream biology branches. Sequestering actin shifts the polymerization equilibrium that cells use to crawl, which is why thymosin beta-4 promotes migration of keratinocytes, endothelial cells, myoblasts and progenitor cells [5]. The TB-500 mechanism of action discussed in research-community contexts is this actin biology read forward into repair. The open question is dose and molecule: the crystallographic and migration work characterizes the full-length protein and its motif, and whether the isolated heptapeptide reproduces the same downstream signaling at the doses used in peptide research has not been tested in controlled human trials [13].

## Thymosin Beta-4: The Parent Protein Behind TB-500

Thymosin beta-4 is a ubiquitous 43-amino-acid peptide (gene TMSB4X, UniProt P62328) and the body's principal G-actin-sequestering molecule. The LKKTETQ segment at residues 17-23 — the actin-binding core — is exactly what TB-500 reproduces. Reading the efficacy literature accurately means reading it as thymosin beta-4 data unless a study specifically used the fragment, because most of it did.

A foundational review frames the protein as a multifunctional regenerative peptide: it binds actin and promotes cell mobilization and stem-cell activity, decreases myofibroblast number to reduce scarring, is released by platelets and macrophages after injury to limit apoptosis and inflammation, and promotes angiogenesis — the rationale that took it into clinical trials for dermal wounds, corneal injury, and heart and CNS repair [5]. A companion review consolidates the animal record across organ systems [9]. None of this makes the heptapeptide a proven human therapy; it maps the biology the fragment inherits and the studies it borrows from.

## How does TB-500 work?

TB-500 carries thymosin beta-4's actin-binding LKKTETQ motif. Full-length thymosin beta-4 sequesters monomeric (G-) actin 1:1 by capping both ends, regulating cytoskeletal dynamics and cell migration [1]; in injury models the protein is linked to migration, angiogenesis, and anti-inflammatory and anti-apoptotic signaling [5]. Whether the isolated 7-mer reproduces these effects at research doses is not established in controlled human trials [13].

## Does TB-500 affect the heart?

In animal models, thymosin beta-4 activated PINCH-ILK-Akt survival signaling, mobilized epicardial progenitor cells, and improved function after coronary ligation [2]; engineered scaffold-released thymosin beta-4 also promoted cardiac repair [14]. But systemic thymosin beta-4 failed to attenuate ischemia-reperfusion injury in a porcine model — a notable null result, and a reason cardiac claims for the compound remain unsettled rather than established [13].

## Does TB-500 have neuroprotective effects on the brain?

In a rat embolic middle-cerebral-artery occlusion study, intraperitoneal thymosin beta-4 at 2 and 12 mg/kg improved neurological function, significant from day 14 through day 56 (p<0.05), while 18 mg/kg gave no significant benefit — a non-monotonic, higher-is-not-better result, with a modeled optimal dose near 3.75 mg/kg [4]. The finding is from the full-length protein in rodents; no human neuroprotection data exist for the fragment.

## Does TB-500 reduce inflammation?

Thymosin beta-4 suppressed corneal NF-kappaB as a potential anti-inflammatory pathway in the eye [11], and in wound-repair work it modulated matrix metalloproteinase expression to support extracellular-matrix remodeling [10]. These are mechanistic anti-inflammatory and remodeling signals reported mainly for the full-length protein in animal and in-vitro models, not human outcomes for the heptapeptide.

## Does TB-500 help wound healing?

In animal and topical models, thymosin beta-4 accelerated re-epithelialization — by 42% at four days and up to 61% at seven days versus saline in a rat full-thickness wound — increased wound contraction and collagen deposition, and even ~10 pg stimulated keratinocyte migration [3]. Recent biomaterials work pairs thymosin beta-4-loaded exosome hydrogels with vascularized wound repair [15]. The figures are animal and in-vitro; they are not a human dosing schedule.

## Reading the evidence map honestly

Set out as a register, the thymosin beta-4 record splits cleanly into what is established and what is not. Established, and reproducibly so: the 1:1 G-actin sequestration structure [1]; the wound-healing figures in rodents [3]; the PINCH-ILK-Akt cardiac survival signaling [2]; the VEGF/HIF-1alpha angiogenic induction [8]; the corneal NF-kappaB and MMP remodeling signals [10][11]; and the single human fact, that intravenous full-length thymosin beta-4 was well tolerated to 1260 mg in a Phase 1 study [6]. These are confirmed in the sense that a cited study measured them.

Not established, and flagged as such: that the isolated heptapeptide reproduces any of this in humans. There is no completed controlled trial of the TB-500 fragment for any indication [13]. The record also carries genuine null and mixed results that resist a clean narrative — systemic thymosin beta-4 did not attenuate porcine ischemia-reperfusion injury, chronic dosing did not improve strength in mdx mice, and the rat stroke dose-response was non-monotonic, with 18 mg/kg underperforming 2 and 12 mg/kg [4][13]. A 2026 Sports Medicine review places the compound among unapproved peptides with favorable animal data but scarce human safety evidence and potential for serious harm [13]. The map is two columns wide, and reading only the left one is how the marketing works.

## Are there any human clinical trials on TB-500?

No completed controlled trials of the TB-500 heptapeptide exist for any indication. Human data exist only for full-length thymosin beta-4: a randomized, placebo-controlled Phase 1 intravenous safety and pharmacokinetic study in 40 healthy volunteers found it well tolerated to 1260 mg with no dose-limiting toxicities, and topical ophthalmic thymosin beta-4 (RGN-259) was studied in dry-eye trials [6]. An injectable acute-MI trial completed and an early injectable stroke trial was withdrawn. Efficacy of the 7-mer in humans is unproven [13]. These are [human clinical trials on thymosin β4](/research), not on the fragment.

---

Legit TB-500 runs the thymosin beta-4 literature like a status check: the seven-mer marked present, the full-length protein where the data actually live marked separately, the human-evidence column returning zero, and FDA's standing quoted straight — a console for verifying claims, not a clinic, a pharmacy, or a place anything is sold.